An open-access review article led by Nemany A.N. Hanafy, Ph.D., a NanoBio4Can MSCA Cofund Postdoctoral Programme Fellow at KUTTAM, Koç University, under the supervision of Safacan Kolemen, Ph.D. (Koç University), has been published in RSC Advances.
The review article titled “Liposomal nanoparticles as a drug delivery system for improved treatment of multiple myeloma” provides a detailed overview of the latest developments in liposomal targeting of multiple myeloma as an innovative approach moving toward clinical trials. This review highlights the key features of liposomal nanotechnology, recent advances in chemotherapeutic-loaded liposomal nanoparticles, and the evolving design of liposomes functionalized with specific molecules or antibodies for targeted therapy of multiple myeloma. Liposome-encapsulated chemotherapeutic agents, administered either alone or in combination, are summarized with representative examples and detailed explanations for each method. Additionally, this review discusses numerous antibodies and targeting molecules that have recently been used to functionalize liposomes for multiple myeloma treatment, along with current limitations and future perspectives, offering a comprehensive and up-to-date overview.
Read the full article: pubs.rsc.org
This work aligns with the research scope of the NanoBio4Can (“Nanobiotechnologies for Innovative Therapeutic Approaches for Cancer”) programme, a Marie Skłodowska-Curie COFUND postdoctoral fellowship programme funded by the European Union and TÜBİTAK, which supports interdisciplinary research at the interface of nanotechnology, biomedicine, and cancer therapy.
NanoBio4Can Project is funded by the European Union and TÜBİTAK. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or TÜBİTAK. Neither the European Union nor the TÜBİTAK can be held responsible for them.
